880135P
Avanti
DSPE-PEG (2000) 羧酸
Avanti Research™ - A Croda Brand
别名:
1,2-二硬脂酰-sn-甘油-3-磷酸乙醇胺-N-[羧基(聚乙二醇)-2000] (钠盐)
产品名称
DSPE-PEG (2000) 羧酸, Avanti Research™ - A Croda Brand 880135P, powder
方案
>99% (TLC)
表单
powder
包装
pkg of 1 × 10 mg (880135P-10mg)
pkg of 1 × 100 mg (880135P-100mg)
pkg of 1 × 25 mg (880135P-25mg)
pkg of 1 × 50 mg (880135P-50mg)
pkg of 1 × 500 mg (880135P-500mg)
制造商/商品名称
Avanti Research™ - A Croda Brand 880135P
运输
dry ice
储存温度
−20°C
SMILES字符串
[H][C@@](COP([O-])(OCCNC(C/C=C\OOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOCCOOCC(O)=O)=O)=O)(OC(CCCCCCCCCCCCCCCCC)=O)COC(CCCCCCCCCCCCCCCCC)=O.C=C.C=C.C=C.C=C.C=C.C=C.C=C.C=C.C=C.C=C.C=C.C=C.C=C.C=C.C=C.C=C.C=C.C=C.C=C.C=C.C=C.C=C.C=C.C=C.C=C.C=C.C=C.C=C.C=
一般描述
羧酸易溶于水和乙醇等极性溶剂。DSPE-PEG（2000）羧酸由2kDa的亲水性聚乙二醇（PEG）链组成。
应用
DSPE-PEG（2000）羧酸用于：
- 将整联蛋白 α-2（ITGA2）抗体共价结合至脂质体表面
- 制备阿托西班结合的脂质体
- 制备双重互补脂质体
生化/生理作用
DSPE-PEG（2000）羧酸增加脂质体的血液循环时间。DSPE-PEG（2000）羧酸的羧基有助于和抗体共价结合。
包装
20 mL 透明玻璃螺旋盖小瓶 (880135P-500 mg)
5 mL 棕色玻璃螺旋盖小瓶 (880135P-10 mg)
5 mL 棕色玻璃螺旋盖小瓶 (880135P-100 mg)
5 mL 棕色玻璃螺旋盖小瓶 (880135P-25 mg)
5 mL 棕色玻璃螺旋盖小瓶 (880135P-50 mg)
法律信息
Avanti Research is a trademark of Avanti Polar Lipids, LLC
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
No data available
闪点(°C)
No data available
Mohammad Mashreghi et al.
Nanoscale research letters, 15(1), 101-101 (2020-05-10)
In this study, we have surface-functionalized PEGylated-nanoliposomal doxorubicin (DOX) with anti-EpCAM (epithelial cell adhesion molecule) aptamer via post-insertion of anti-EpCAM aptamer-conjugated DSPE-mPEG2000 into Caelyx® (ED-lip). The size, charge, release profile, and cytotoxicity and cellular uptake of formulation were determined. The
ITGA2 as a potential nanotherapeutic target for glioblastoma
Guo P, et al.
Scientific reports, 9(1), 6195-6195 (2019)
Carboxylic Acid: Key Role in Life Sciences (2019)
Dual complementary liposomes inhibit triple-negative breast tumor progression and metastasis
Guo P, et al.
Science advances, 5(3), eaav5010-eaav5010 (2019)
Feifei Yang et al.
Small (Weinheim an der Bergstrasse, Germany), 16(7), e1906360-e1906360 (2020-01-24)
Hepatotoxicity is a key concern in the clinical translation of nanotherapeutics because preclinical studies have consistently shown that nanotherapeutics accumulates extensively in the liver. However, clinical-stage nanotherapeutics have not shown increased hepatotoxicity. Factors that can contribute to the hepatotoxicity of
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持